BioCentury
ARTICLE | Clinical News

Zadaxin thymosin alpha 1: Phase III data; marketed in Asia

June 1, 1998 7:00 AM UTC

SCLN published in Hepatology results from a single site involving 98 patients out of a total of 158 patients enrolled in SCLN's Phase III trial in Taiwan (see BioCentury, Aug. 5, 1996). Among patients given 1.6 mg of Zadaxin twice weekly for 6 months, 40.6 percent had no detectable virus (HBV) or hepatitis B e antigen (HBe) at 18 months compared to 9.4 percent in the placebo group (p=0.004). ...